Claudia Haferlach

41PUBLICATIONS
216CO-AUTHORS
Regenerative medicine (incl. stem cells)Gene and molecular therapyMedical mycologyBioinformatic methods developmentHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Apr 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

|Apr 20, 2026
IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

|Mar 31, 2026
Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Umair Munawar, Johanna Thurner, Silvia Nerreter

|Mar 25, 2026
Myeloid Neoplasms With a t(5;12)(q31;p13) and an Associated ETV6::ACSL6 Gene Fusion Are Diagnostically Challenging and Have a Poor Prognosis.

Bettina Balk, Marietta Truger, Wencke Walter

Pageof 7

Frequent Collaborators

25 joint publications

Torsten Haferlach

18 joint publications

Wolfgang Kern

14 joint publications

Manja Meggendorfer

13 joint publications

Stephan Hutter